Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis
Status:
Completed
Trial end date:
2006-10-19
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the efficacy and safety of 3 dose levels of
oral ERB-041 administered daily for 12 weeks versus placebo in subjects with active
rheumatoid arthritis who have had a suboptimal response to therapy with stable doses of
methotrexate (MTX).